Yahoo · Sep 2, 2026
Amgen Stock Signals Its Confidence. The Market Agrees.
The real bet is on what lies beyond this year's performance: a pipeline that could change everything.
NASDAQ · JNJ
Johnson & Johnson
Healthcare · Drug Manufacturers - General
$275.21
Up+$4.02 (+1.48%)
Updated Sep 3, 2026, 5:56 AM
SID Score
7.8/10
Composite research score
Smart Money
56/100
Neutral
- Market cap
- 505.78B
- P/E ratio
- 20.3
- Dividend yield
- 1.87%
- 52-week range
- $199.91 – $276.47
- Volume
- 7.91M
- Avg. volume
- 8.82M
Price performance
JNJ price history
1M range · 21 trading sessions · Daily adjusted prices
JNJ closed at $275.21 after 21 trading sessions, up 6.84% for the selected period.
- Last close
- $275.21
- Period change
- +6.84%
- Period low
- $256.98
- Period high
- $275.21
Daily close
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Sep 2, 2026 | $274.74 | $281.07 | $273.53 | $275.21 | 7.91M |
| Sep 1, 2026 | $270.83 | $271.91 | $267.02 | $271.19 | 6.04M |
| Aug 31, 2026 | $267.125 | $267.77 | $265.17 | $265.85 | 7.9M |
| Aug 28, 2026 | $265.78 | $268.38 | $264.27 | $268.04 | 5.77M |
| Aug 27, 2026 | $268.45 | $268.45 | $263.83 | $265.77 | 7.31M |
| Aug 26, 2026 | $271.97 | $272.905 | $269.55 | $270.00 | 7.22M |
| Aug 25, 2026 | $271.00 | $273.8021 | $270.175 | $273.14 | 4.69M |
| Aug 24, 2026 | $269.74 | $273.98 | $268.57 | $273.04 | 5.44M |
| Aug 21, 2026 | $267.83 | $272.655 | $267.00 | $270.24 | 6.19M |
| Aug 20, 2026 | $273.40 | $273.40 | $267.37 | $267.37 | 6.48M |
| Aug 19, 2026 | $272.995 | $276.47 | $270.56 | $273.41 | 7.73M |
| Aug 18, 2026 | $267.67 | $271.73 | $266.33 | $271.11 | 7.84M |
| Aug 17, 2026 | $258.87 | $264.2775 | $258.01 | $262.37 | 5.52M |
| Aug 14, 2026 | $260.65 | $261.71 | $259.16 | $260.35 | 5M |
| Aug 13, 2026 | $261.725 | $262.62 | $259.6475 | $262.08 | 4.85M |
| Aug 12, 2026 | $256.00 | $261.41 | $255.255 | $260.86 | 4.63M |
| Aug 11, 2026 | $261.23 | $264.15 | $258.36 | $259.80 | 5.95M |
| Aug 10, 2026 | $259.06 | $262.00 | $258.55 | $261.81 | 8.99M |
| Aug 7, 2026 | $255.89 | $259.60 | $255.12 | $259.24 | 6.53M |
| Aug 6, 2026 | $261.71 | $262.11 | $255.28 | $256.98 | 6.93M |
| Aug 5, 2026 | $255.25 | $259.32 | $254.47 | $257.59 | 6.47M |
Latest JNJ news
The latest Smart Investors Daily articles mentioning JNJ.
Stock researchCompany · Overview
JNJ research
Overview
Company profile and research snapshot.
Company profile
Johnson & Johnson is the world's largest and most diverse healthcare firm. It has two divisions: innovative medicine and medtech. These now represent all of the company's sales following the divestment of the consumer business, Kenvue, in 2023. After restructurings in 2023-24, the drug division focuses on three main therapeutic areas: immunology, oncology, and neurology. Geographically, just over half of total revenue is generated in the United States.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- Buy
- Average target
- $207.08
- Implied upside
- —
- Analysts
- 18
| Date | Firm | Rating | Target |
|---|---|---|---|
| Aug 6, 2026 | Guggenheim | Buy | — |
| Aug 3, 2026 | Wells Fargo | Overweight | — |
| Jul 17, 2026 | Guggenheim | Buy | — |
| Jul 16, 2026 | Wells Fargo | Overweight | — |
| Jul 16, 2026 | RBC Capital | Outperform | — |
News briefing
Generated Sep 2, 2026, 9:18 PM
Why Is JNJ Up Today?
Johnson & Johnson gained 1.48% today, buoyed primarily by UBS Securities raising its price target to $320 and maintaining a Buy rating on the stock. The upgrade reflects confidence in J&J's robust drug pipeline and growth prospects, contributing to broader healthcare sector strength on Wednesday.
Bottom line: JNJ's 1.48% gain today reflects analyst confidence in its drug pipeline and dividend stability, with UBS's elevated price target providing concrete support for the bullish case. However, investors should balance this optimism against execution risks in converting pipeline innovations to profits and ongoing legal liabilities that could pressure future earnings and cash flow.
Yahoo · Sep 2, 2026
Sector Update: Healthcare Stocks Advance Late Afternoon
Healthcare stocks were higher late Wednesday afternoon, with the NYSE Healthcare Index and the State
Yahoo · Sep 2, 2026
ISRG Stock: The Best House On The Block Costs The Most
In the world of robotic surgery, one company is both the undisputed leader and the most expensive option, forcing investors to ask if operational excellence is worth the premium.
Yahoo · Sep 2, 2026
The Wide Divide Priced Into Boston Scientific Stock
The market's valuation reflects a wide breadth of potential outcomes for the company, exposing shareholders to the full magnitude of that underlying risk.
AI research layers
Interpretive context generated from the platform’s current data sources.
Johnson & Johnson Stock Performance
Johnson & Johnson shares traded at $271.19, reflecting a modest daily decline of 0.38% per SID market data. Over the trailing one-month period, JNJ has gained 6.6%, while the three-month return stands at an impressive 21.67%, underscoring sustained upward momentum. On a twelve-month basis, the stock has appreciated 33.93%, significantly outperforming broader healthcare sector benchmarks. Technical indicators show JNJ trading well above its 50-day moving average of $259.69 and its 200-day moving average of $240.88, according to Massive/Polygon data, confirming a firmly established uptrend. The 14-day RSI reads 61.5, indicating bullish momentum without yet entering overbought territory. Average daily volume stands at approximately 8.82 million shares, supporting orderly price discovery. The stock's beta of 0.349 reflects considerably lower volatility than the broader market, consistent with JNJ's defensive healthcare profile and its $505.8 billion market capitalization.
Johnson & Johnson Valuation Analysis
Johnson & Johnson currently trades at a price-to-earnings ratio of 20.30, according to SID market data, positioning it within a moderate valuation range for large-cap healthcare companies. The PEG ratio stands at 1.91, suggesting the stock is priced near fair value relative to its expected earnings growth trajectory. Per SEC filings and market data, JNJ's price-to-book ratio of 6.43 reflects the premium investors assign to the company's extensive pharmaceutical pipeline, brand portfolio, and MedTech franchise. The dividend yield sits at 2.45%, maintaining JNJ's longstanding reputation as a reliable income-generating holding for conservative portfolios. With a market capitalization of approximately $505.8 billion, Johnson & Johnson remains one of the largest healthcare companies globally. The combination of a sub-1.0 beta at 0.349 and a consistent dividend underscores the stock's positioning as a defensive equity within the healthcare sector.
Smart Money Activity for JNJ
Johnson & Johnson's composite smart money score stands at 56 out of 100 with a neutral signal, according to SID market data. Institutional positioning is the strongest component, scoring a perfect 25 out of 25, indicating robust confidence among major fund managers and asset allocators. Congressional trading activity scores 13.2 out of 25, reflecting moderate engagement by lawmakers disclosed through public filings. Dark pool activity registers at 9.5 out of 25, suggesting below-average large block transaction volumes in off-exchange venues. Per SEC Form 4 filings, insider activity has been notable with 19 transactions recorded over the past 90 days, comprising 8 purchases and 11 sales, resulting in a net selling posture. The insider component scores 8.6 out of 25, the lowest among the four sub-categories. While institutional holders demonstrate maximum conviction per 13F institutional filings, the mixed insider activity and subdued dark pool readings temper the overall smart money assessment to a balanced, neutral stance.
Johnson & Johnson Earnings Outlook
Johnson & Johnson has demonstrated consistent earnings execution across its most recent quarterly reports. Per company earnings reports, the most recent quarter posted earnings per share of $2.90 against a consensus estimate of $2.85, representing a positive surprise of $0.05. The prior quarter delivered EPS of $2.70 versus expectations of $2.67, another modest beat of $0.03. In the quarter ending January 2026, JNJ reported a slight miss at $2.46 compared to the $2.47 estimate, the only shortfall in the four-quarter sequence. The September 2025 quarter produced EPS of $2.80, exceeding the $2.7848 estimate according to analyst estimates. This pattern of three beats in four quarters reflects operational stability and disciplined cost management. The sequential EPS progression from $2.46 to $2.90 across the trailing four quarters demonstrates an improving earnings trajectory, consistent with management's guidance around pharmaceutical portfolio strength and MedTech segment recovery.
Wall Street Analyst Ratings for JNJ
Wall Street coverage of Johnson & Johnson reflects a uniformly constructive outlook, per SID consensus data. Guggenheim reiterated its Buy rating on August 6, 2026, maintaining its positive stance following the company's earnings report. Wells Fargo similarly reaffirmed its Overweight rating on August 3, 2026, signaling continued conviction in JNJ's forward trajectory. Earlier in July 2026, RBC Capital maintained its Outperform rating, while both Guggenheim and Wells Fargo also reiterated their respective bullish calls around the mid-July earnings release, according to Wall Street analyst reports. Notably, none of the five most recent rating actions involved a downgrade or a shift to a negative stance, and all represented reiterations of previously held positive views. The consensus among these three covering firms remains decisively tilted toward a buy-equivalent recommendation. With JNJ trading at a P/E of 20.30 and delivering consistent earnings beats, analyst confidence appears anchored in the company's demonstrated fundamental execution and defensive growth characteristics.
